Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF) (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $300000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 25.0% year-over-year to $300000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 18.75% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, down 12.5% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $300000.0, down from $400000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for FULC reached as high as $700000.0 in Q2 2022 and fell as low as $300000.0 in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $470941.2 across 5 years, with a median of $479000.0 in 2024.
• Across the five-year window, Depreciation & Amortization (CF) increased 20.0% in 2023 and slumped 33.33% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $591000.0 in 2022, then fell by 9.31% to $536000.0 in 2023, then decreased by 25.37% to $400000.0 in 2024, then changed by 0.0% to $400000.0 in 2025, then slipped by 25.0% to $300000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $300000.0 in Q1 2026, $400000.0 in Q4 2025, and $300000.0 in Q3 2025.